Initial Workup of Pancreatic Masses

Primary Imaging: Pancreas Protocol CT

The National Comprehensive Cancer Network recommends that all patients with suspected pancreatic cancer should undergo a dedicated pancreas protocol CT scan with intravenous contrast as the primary initial imaging modality, which achieves 70-85% accuracy in predicting resectability and provides critical assessment of vascular involvement 1, 2
The pancreas protocol CT must include specific technical parameters, such as dual-phase contrast-enhanced imaging with late arterial/pancreatic phase and portal venous phase, and thin-slice acquisition using submillimeter axial sections with multiplanar reformations 1, 2
Chest imaging should be included to evaluate for pulmonary metastases, as recommended by the National Comprehensive Cancer Network 3, 4

The American College of Radiology recommends MRI with MRCP as the preferred alternative when IV contrast is contraindicated, offering advantages over CT including superior soft-tissue contrast and better characterization of liver lesions 1, 5, 2
MRI with MRCP provides superior demonstration of ductal communication and is preferred for assessing worrisome features in incidentally discovered pancreatic cysts 5

The National Comprehensive Cancer Network recommends obtaining baseline laboratory tests, including liver function tests, CA 19-9 tumor marker, fasting glucose or HbA1c, and lipase or amylase, to assess biliary obstruction and detect pancreatic cancer 6, 7

The National Comprehensive Cancer Network recommends proceeding directly to surgical consultation without tissue diagnosis for resectable disease, and obtaining tissue via EUS-FNA for borderline resectable or unresectable disease 1, 3, 7
Tissue diagnosis is required before systemic therapy for metastatic disease, as recommended by the Journal of Clinical Oncology 8, 4

The Journal of Clinical Oncology recommends documenting baseline ECOG performance status and comorbidity profile, which directly impact treatment eligibility, and considering aggressive regimens like FOLFIRINOX for ECOG 0-1 patients with favorable comorbidities 8, 4

The National Comprehensive Cancer Network recommends MRI with gadolinium and MRCP as the preferred alternative when IV contrast is contraindicated, offering superior soft-tissue contrast and better characterization of liver lesions 9
MRI with MRCP has 96.8% sensitivity and 90.8% specificity for distinguishing pancreatic lesions, compared to 80.6% and 86.4% for CT, according to the American College of Radiology 10
MRI is superior for detecting isoattenuating tumors, which account for 5-17% of pancreatic cancers, and has a sensitivity of 98% for detecting small tumors <2 cm 11
The American College of Radiology recommends against using EUS-FNA for initial characterization of small pancreatic cysts (<2.5 cm) due to the low risk of malignant transformation and procedural risks 11
Transperitoneal biopsy carries a risk of tumor seeding and false negatives, with approximately 5% of pancreaticoduodenectomies revealing benign disease, as reported in the journal Gut 12